Balo Andrew K's Form 4 filing
Dexcom Inc (DXCM) · filed Jul 8, 2021
- Accession no.
- 0001093557-21-000177
- Filed
- Jul 8, 2021
- Trade date
- Jul 6, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $1.28M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Balo Andrew KCIK 0001323190 | Officer (*) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2021 | Common Stock | SSaleDisposed | −578 | $428.51F2 | −$247,678.78 | 15,805 | Indirect | |
| Jul 6, 2021 | Common Stock | SSaleDisposed | −400 | $429.33F4 | −$171,732 | 15,405 | Indirect | |
| Jul 6, 2021 | Common Stock | SSaleDisposed | −1,710 | $430.56F5 | −$736,257.6 | 13,695 | Indirect | |
| Jul 6, 2021 | Common Stock | SSaleDisposed | −286 | $432.05F6 | −$123,566.3 | 13,409 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $428.125 to $429.060. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $429.141 to $429.401. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $430.270 to $430.919. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $431.455 to $432.050. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
Remarks
*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development